Oncologists expect Avastin Rxs to more than double: survey
March 11 2008
A recent survey of oncologists indicates market share for Genentech's Avastin could more than double as a first-line and second-line ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.